100 related articles for article (PubMed ID: 2931625)
1. Muscarine-binding sites localized to cortical dopamine terminals.
Liskowsky DR; Potter LT
Neurosci Lett; 1985 Jul; 58(2):229-33. PubMed ID: 2931625
[TBL] [Abstract][Full Text] [Related]
2. Presynaptic muscarinic receptors on dopaminergic terminals in the nucleus accumbens.
De Belleroche J; Kilpatrick IC; Birdsall NJ; Hulme EC
Brain Res; 1982 Feb; 234(2):327-37. PubMed ID: 7059834
[TBL] [Abstract][Full Text] [Related]
3. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment.
Joyce JN
Exp Neurol; 1991 Sep; 113(3):277-90. PubMed ID: 1833220
[TBL] [Abstract][Full Text] [Related]
4. Ontogeny of dopaminergic function in the rat midbrain tegmentum, corpus striatum and frontal cortex.
Noisin EL; Thomas WE
Brain Res; 1988 Jun; 469(1-2):241-52. PubMed ID: 3401800
[TBL] [Abstract][Full Text] [Related]
5. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area.
Sesack SR; Pickel VM
J Comp Neurol; 1992 Jun; 320(2):145-60. PubMed ID: 1377716
[TBL] [Abstract][Full Text] [Related]
6. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain.
Wilmot CA; Szczepanik AM
Brain Res; 1989 May; 487(2):288-98. PubMed ID: 2525063
[TBL] [Abstract][Full Text] [Related]
7. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
8. Effects of neonatal thermal lesioning of the mesocortical dopaminergic projection on the development of the rat prefrontal cortex.
Kalsbeek A; Buijs RM; Hofman MA; Matthijssen MA; Pool CW; Uylings HB
Brain Res; 1987 Mar; 429(1):123-32. PubMed ID: 3032369
[TBL] [Abstract][Full Text] [Related]
9. Serotonin-S2 and dopamine-D2 receptors are the same size in membranes.
Brann MR
Biochem Biophys Res Commun; 1985 Dec; 133(3):1181-6. PubMed ID: 2935151
[TBL] [Abstract][Full Text] [Related]
10. Self-stimulation of the nucleus accumbens and ventral tegmental area of Tsai attenuated by microinjections of spiroperidol into the nucleus accumbens.
Mogenson GJ; Takigawa M; Robertson A; Wu M
Brain Res; 1979 Aug; 171(2):247-59. PubMed ID: 572734
[TBL] [Abstract][Full Text] [Related]
11. No change in neostriatal D-2 dopamine receptors after NMDA lesions of rat prefrontal cortex.
Bridge S; Christie MJ; Beart PM
Pharmacol Biochem Behav; 1986 Jun; 24(6):1829-32. PubMed ID: 2942950
[TBL] [Abstract][Full Text] [Related]
12. Chronic haloperidol does not increase specific dopamine receptor binding in rat frontal cortex.
Meller E; Bohmaker K; Rosengarten H; Friedhoff AJ
Res Commun Chem Pathol Pharmacol; 1982 Sep; 37(3):323-32. PubMed ID: 7178646
[TBL] [Abstract][Full Text] [Related]
13. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
Hancock AA; Marsh CL
Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
[TBL] [Abstract][Full Text] [Related]
14. Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats.
Araki T; Tanji H; Fujihara K; Kato H; Imai Y; Mizugaki M; Itoyama Y
J Neural Transm (Vienna); 2000; 107(8-9):873-84. PubMed ID: 11041269
[TBL] [Abstract][Full Text] [Related]
15. Ontogeny of open field activity in rats after neonatal lesioning of the mesocortical dopaminergic projection.
Kalsbeek A; de Bruin JP; Matthijssen MA; Uylings HB
Behav Brain Res; 1989 Mar; 32(2):115-27. PubMed ID: 2923656
[TBL] [Abstract][Full Text] [Related]
16. Cortical ablation fails to influence striatal dopamine target cell supersensitivity induced by nigrostriatal denervation in the rat.
Paturle L; Fage D; Fourrier O; Vernier P; Feuerstein C; Demenge P; Scatton B
Brain Res; 1987 Feb; 402(2):383-6. PubMed ID: 3828803
[TBL] [Abstract][Full Text] [Related]
17. D-2 dopamine receptors in the frontal cortex of rat and human.
Liskowsky DR; Potter LT
Life Sci; 1985 Apr; 36(16):1551-9. PubMed ID: 3982225
[TBL] [Abstract][Full Text] [Related]
18. Computer imaging and analysis of dopamine (D2) and serotonin (S2) binding sites in rat basal ganglia or neocortex labeled by [3H]spiroperidol.
Altar CA; Kim H; Marshall JF
J Pharmacol Exp Ther; 1985 May; 233(2):527-38. PubMed ID: 3889277
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of [3H]spiroperidol binding to rat forebrain sections: plasticity of neostriatal dopamine receptors after nigrostriatal injury.
Neve KA; Altar CA; Wong CA; Marshall JF
Brain Res; 1984 Jun; 302(1):9-18. PubMed ID: 6428705
[TBL] [Abstract][Full Text] [Related]
20. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum.
Boyson SJ; McGonigle P; Luthin GR; Wolfe BB; Molinoff PB
J Pharmacol Exp Ther; 1988 Mar; 244(3):987-93. PubMed ID: 2908050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
